Login Register Cart 0
Review Article

慢性腰痛：目前的药物治疗疗法和一种新的生物学方法

卷 26, 期 6, 2019

页: [1019 - 1026] 页: 8

弟呕挨: 10.2174/0929867325666180514102146

价格: $65

摘要

慢性腰痛（CLBP）综合征是全球长期致残的主要原因之一。 随着平均预期寿命的增加，CLBP的患病率显着上升。 CLBP由急性腰痛的慢性化病引起。 导致CLBP危机的因素很多; 常见的病因发生因素包括例如椎间关节的功能性阻塞。 CLBP的治疗很复杂。 治疗的一个重要部分包括疼痛药物疗法，其中使用了几组药物。 问题在于许多传统使用的药物的副作用。 因此，正在寻求新的和更安全的治疗方法。 CLBP药理学的创新选择包括含有胶原蛋白的注射剂，可以与其他传统使用的药物结合使用，这有助于减少剂量并提高CLBP治疗的整体安全性。

关键词: 慢性腰痛，慢性疼痛管理，慢性疼痛的药物治疗，疼痛的安全治疗，疼痛控制，含胶原蛋白的注射。

« Previous Next »
[1]
Balagué, F.; Mannion, A.F.; Pellisé, F.; Cedraschi, C. Non-specific low back pain. Lancet, 2012, 379(9814), 482-491.
[2]
Shmagel, A.; Foley, R.; Ibrahim, H. Epidemiology of chronic low back pain in US adults: Data from the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res. (Hoboken), 2016, 68(11), 1688-1694.
[3]
Juniper, M.; Le, T.K.; Mladsi, D. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: A literature-based review. Expert Opin. Pharmacother., 2009, 10(16), 2581-2592.
[4]
Freburger, J.K.; Holmes, G.M.; Agans, R.P.; Jackman, A.M.; Darter, J.D.; Wallace, A.S.; Castel, L.D.; Kalsbeek, W.D.; Carey, T.S. The rising prevalence of chronic low back pain. Arch. Intern. Med., 2009, 169(3), 251-258.
[5]
Dagenais, S.; Tricco, A.C.; Haldeman, S. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. Spine J., 2010, 10(6), 514-529.
[6]
Delitto, A.; George, S.Z.; Van Dillen, L.R.; Whitman, J.M.; Sowa, G.; Shekelle, P.; Denninger, T.R.; Godges, J.J. Low back pain. J. Orthop. Sports Phys. Ther., 2012, 42(4), A1-A57.
[7]
Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Phys. Ther., 2001, 81(10), 1641-1674.
[8]
Smart, K.M.; Blake, C.; Staines, A.; Thacker, M.; Doody, C. Mechanisms-based classifications of musculoskeletal pain: part 1 of 3: symptoms and signs of central sensitisation in patients with low back (± leg) pain. Man. Ther., 2012, 17(4), 336-344.
[9]
Garland, E.L. Pain processing in the human nervous system: A selective review of nociceptive and biobehavioral pathways. Prim. Care, 2012, 39(3), 561-571.
[10]
Nijs, J.; Malfliet, A.; Ickmans, K.; Baert, I.; Meeus, M. Treatment of central sensitization in patients with ‘unexplained’ chronic pain: an update. Expert Opin. Pharmacother., 2014, 15(12), 1671-1683.
[11]
Binder, D.S.; Nampiaparampil, D.E. The provocative lumbar facet joint. Curr. Rev. Musculoskelet. Med., 2009, 2(1), 15-24.
[12]
Cohen, S.P.; Raja, S.N. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. Anesthesiology, 2007, 106(3), 591-614.
[13]
Lurie, J.; Tomkins-Lane, C. Management of lumbar spinal stenosis. BMJ, 2016, 352, 6234.
[14]
Manchikanti, L.; Singh, V.; Pampati, V.; Damron, K.S.; Barnhill, R.C.; Beyer, C.; Cash, K.A. Evaluation of the relative contributions of various structures in chronic low back pain. Pain Physician, 2001, 4(4), 308-316.
[15]
Deyo, R.A.; Bryan, M.; Comstock, B.A.; Turner, J.A.; Heagerty, P.; Friedly, J.; Avins, A.L.; Nedeljkovic, S.S.; Nerenz, D.R.; Jarvik, J.G. Trajectories of symptoms and function in older adults with low back disorders. Spine (Phila Pa 1976.), 2015, 40(17), 1352-1362.
[16]
Amirdelfan, K.; McRoberts, P.; Deer, T.R. The differential diagnosis of low back pain: A primer on the evolving paradigm. Neuromodulation, 2014, 17(Suppl.), 211-217.
[17]
Davis, P.C.; Wippold, F.J., II; Brunberg, J.A.; Cornelius, R.S.; De La Paz, R.L.; Dormont, P.D.; Gray, L.; Jordan, J.E.; Mukherji, S.K.; Seidenwurm, D.J.; Turski, P.A.; Zimmerman, R.D.; Sloan, M.A. ACR appropriateness criteria on low back pain. J. Am. Coll. Radiol., 2009, 6(6), 401-407.
[18]
Chou, R.; Qaseem, A.; Snow, V.; Casey, D.; Cross, J.T., Jr; Shekelle, P.; Owens, D.K. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann. Intern. Med., 2007, 147(7), 478-491.
[19]
Tan, A.; Zhou, J.; Kuo, Y.F.; Goodwin, J.S. Variation among primary care physicians in the use of imaging for older patients with acute low back pain. J. Gen. Intern. Med., 2016, 31(2), 156-163.
[20]
Boden, S.D.; Davis, D.O.; Dina, T.S.; Patronas, N.J.; Wiesel, S.W. Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation. J. Bone Joint Surg. Am., 1990, 72(3), 403-408.
[21]
Monie, A.P.; Fazey, P.J.; Singer, K.P. Low back pain misdiagnosis or missed diagnosis: Core principles. Man. Ther., 2016, 22, 68-71.
[22]
Allegri, M.; Montella, S.; Salici, F.; Valente, A.; Marchesini, M.; Compagnone, C.; Baciarello, M.; Manferdini, M.E.; Fanelli, G. Mechanisms of low back pain: A guide for diagnosis and therapy. F1000 Res., 2016, 5, 5.
[23]
Graham, G.G.; Davies, M.J.; Day, R.O.; Mohamudally, A.; Scott, K.F. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology, 2013, 21(3), 201-232.
[24]
Jaeschke, H. Acetaminophen: Dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig. Dis., 2015, 33(4), 464-471.
[25]
Machado, G.C.; Maher, C.G.; Ferreira, P.H.; Pinheiro, M.B.; Lin, C.W.; Day, R.O.; McLachlan, A.J.; Ferreira, M.L. Efficacy and safety of paracetamol for spinal pain and osteo-arthritis: Systematic review and meta-analysis of randomised placebo controlled trials. Bri Ed. J., 2015, 350, 1225.
[26]
Enthoven, W.T.; Roelofs, P.D.; Deyo, R.A.; van Tulder, M.W.; Koes, B.W. Non-steroidal anti-inflammatory drugs for chronic low back pain., Cochrane Database Syst. Rev.,. 2016. 2CD012087
[27]
Baron, R.; Binder, A.; Attal, N.; Casale, R.; Dickenson, A.H.; Treede, R.D. Neuropathic low back pain in clinical practice. Eur. J. Pain, 2016, 20(6), 861-873.
[28]
Gurwitz, J.H.; Everitt, D.E.; Monane, M.; Glynn, R.J.; Choodnovskiy, I.; Beaudet, M.P.; Avorn, J. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J. Gerontol. A Biol. Sci. Med. Sci., 1996, 51(2), M74-M79.
[29]
Pavlicević, I.; Kuzmanić, M.; Rumboldt, M.; Rumboldt, Z. Interaction between antihypertensives and NSAIDs in primary care: A controlled trial. Can. J. Clin. Pharmacol., 2008, 15(3), e372-e382.
[30]
Snowden, S.; Nelson, R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol. Rev., 2011, 19(4), 184-191.
[31]
Oka, Y.; Okamoto, K.; Kawashita, N.; Shirakuni, Y.; Takagi, T. Meta-analysis of the risk of upper gastrointestinal hemorrhage with combination therapy of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs. Biol. Pharm. Bull., 2014, 37(6), 947-953.
[32]
Anglin, R.; Yuan, Y.; Moayyedi, P.; Tse, F.; Armstrong, D.; Leontiadis, G.I. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: A systematic review and meta-analysis. Am. J. Gastroenterol., 2014, 109(6), 811-819.
[33]
Warkentin, A.E.; Donadini, M.P.; Spencer, F.A.; Lim, W.; Crowther, M. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: A systematic review and meta-analysis. J. Thromb. Haemost., 2012, 10(4), 512-520.
[34]
Machado, G.C.; Maher, C.G.; Ferreira, P.H.; Day, R.O.; Pinheiro, M.B.; Ferreira, M.L. Non-steroidal anti-inflammatory drugs for spinal pain: A systematic review and meta-analysis. Ann. Rheum. Dis., 2017, 76(7), 1269-1278.
[35]
Stamer, U.M.; Stüber, F. The pharmacogenetics of analgesia. Expert Opin. Pharmacother., 2007, 8(14), 2235-2245.
[36]
Farquhar-Smith, P.; Gubbay, A. Tramadol and acetaminophen combination for chronic non-cancer pain. Expert Opin. Pharmacother., 2013, 14(16), 2297-2304.
[37]
Mattia, C.; Coluzzi, F. A look inside the association codeine-paracetamol: Clinical pharmacology supports analgesic efficacy. Eur. Rev. Med. Pharmacol. Sci., 2015, 19(3), 507-516.
[38]
Chaparro, L.E.; Furlan, A.D.; Deshpande, A.; Mailis-Gagnon, A.; Atlas, S.; Turk, D.C. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst. Rev., 2013, (8), CD004959.
[39]
Reinecke, H.; Weber, C.; Lange, K.; Simon, M.; Stein, C.; Sorgatz, H. Analgesic efficacy of opioids in chronic pain: Recent meta-analyses. Br. J. Pharmacol., 2015, 172(2), 324-333.
[40]
Abdel Shaheed, C.; Maher, C.G.; Williams, K.A.; Day, R.; McLachlan, A.J. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: A systematic review and meta-analysis. JAMA Intern. Med., 2016, 176(7), 958-968.
[41]
Chey, W.D.; Webster, L.; Sostek, M.; Lappalainen, J.; Barker, P.N.; Tack, J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N. Engl. J. Med., 2014, 370(25), 2387-2396.
[42]
Davis, M.P.; Goforth, H.W. Oxycodone with an opioid receptor antagonist: A review. J. Opioid. Manag., 2016, 12(1), 67-85.
[43]
Chung, J.W.; Zeng, Y.; Wong, T.K. Drug therapy for the treatment of chronic nonspecific low back pain: Systematic review and meta-analysis. Pain Physician, 2013, 16(6), E685-E704.
[44]
Finnerup, N.B.; Attal, N. Pharmacotherapy of neuropathic pain: Time to rewrite the rulebook? Pain Manag., 2016, 6(1), 1-3.
[45]
Urquhart, D.M.; Hoving, J.L.; Assendelft, W.W.; Roland, M.; van Tulder, M.W. Antidepressants for non-specific low back pain. Cochrane Database Syst. Rev., 2008, (1), CD001703.
[46]
Abdel Shaheed, C.; Maher, C.G.; Williams, K.A.; McLachlan, A.J. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. Eur. J. Pain, 2017, 21(2), 228-237.
[47]
Keitel, W.; Frerick, H.; Kuhn, U.; Schmidt, U.; Kuhlmann, M.; Bredehorst, A. Capsicum pain plaster in chronic non-specific low back pain. Arzneimittelforschung, 2001, 51(11), 896-903.
[48]
Zhang, B.; Li, J.B.; Zhang, D.M.; Ding, Y.; Du, G.H. Analgesic and anti-inflammatory activities of a fraction rich in gaultherin isolated from Gaultheria yunnanensis (FRANCH.) REHDER. Biol. Pharm. Bull., 2007, 30(3), 465-469.
[49]
Ohta, T.; Imagawa, T.; Ito, S. Involvement of transient receptor potential vanilloid subtype 1 in analgesic action of methylsalicylate. Mol. Pharmacol., 2009, 75(2), 307-317.
[50]
Galer, B.S.; Gammaitoni, A.R.; Oleka, N.; Jensen, M.P.; Argoff, C.E. Use of the lidocaine patch 5% in reducing intensity of vari-ous pain qualities reported by patients with low-back pain. Curr. Med. Res. Opin., 2004. 20(Suppl), 2S5-S12
[51]
Casale, R.; Polati, E.; Schweiger, V.; Coluzzi, F.; Bhaskar, A.; Consalvo, M. [Localized neuropathic pain--5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience].Minerva Med. 2014, 105(3), 177-195.
[52]
Waseem, Z.; Boulias, C.; Gordon, A.; Ismail, F.; Sheean, G.; Furlan, A.D. Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst. Rev., 2011, (1), CD008257.
[53]
Valat, J.P.; Rozenberg, S. Local corticosteroid injections for low back pain and sciatica. Joint Bone Spine, 2008, 75(4), 403-407.
[54]
Milani, L. Un nuovo e raffinato trattamento iniettivo delle patologie algiche dell’ apparato locomotore. Le proprieta bio-scaffold dell collagene e suo utilizzo clinico. Med. Biol. (Milano), 2010, 33-15.
[55]
Pavelka, K.; Svobodova, R.; Jarosova, H. MD-Lumbar,MD-Muscle and MD-Neural in the treatment of low back pain. Physiolog. Reg. Med. 2012, 13, 6.

Rights & Permissions Print Cite
Article Metrics
38
5
2
1
© 2024 Bentham Science Publishers | Privacy Policy